Navigation Links
Neuropathic Pain Drug Market (Painful Diabetic Neuropathy, Postherpetic and Trigeminal Neuralgia) Forecast to 2022 in New Report Available at MarketOptimizer.org
Date:9/26/2014

Dallas, Texas (PRWEB) September 26, 2014

With seven promising neuropathic pain (NP) treatments expected to be launched in the coming years, the NP therapeutics market value - covering painful diabetic neuropathy, postherpetic neuralgia and trigeminal neuralgia - is forecast to increase from $2.58 billion in 2012 to $3.53 billion by 2022, at a Compound Annual Growth Rate (CAGR) of 3.19%. According to MarketOptimizer.org's latest report “PharmaPoint: Neuropathic Pain - Global Drug Forecast and Market Analysis to 2022”, seven novel pipeline drugs targeting these three indications will enter the market before 2022. These include Daiichi Sankyo’s DS-5565, Convergence’s CNV-2197944, Grünenthal’s Cebranopadol and Impax’s Eladur. The sales of these pipeline therapies to account for 23.8% of the global NP market by 2022.

This report provides an overview of three neuropathic pain indications - painful diabetic neuropathy, postherpetic neuralgia and trigeminal neuralgia - including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines. It also gives annualized neuropathic pain therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 to 2022.

Complete Report Details Available @ http://www.marketoptimizer.org/pharmapoint-neuropathic-pain-global-drug-forecast-and-market-analysis-to-2022.html .

Key Questions Answered

  • The neuropathic pain market is marked by the presence of a number of unmet needs in current treatments. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the neuropathic pain market?
  • What differences exist in the current disease management across the 3 NP indications, and across the 7 markets?
  • What are the views of KOLs on the present and future landscape of the neuropathic pain market?
  • Several brands of neuropathic pain drugs are due for patent expiry. How will the patent expiries impact the neuropathic pain therapeutics market?
  • The developmental pipeline consists of several novel drugs. Which of these drugs will attain high sales revenues during 2012-2022?

Key Findings

  • The main driver for the expansion of the NP market will be the increasing NP incidence due to 2 main reasons: the growing elderly population
  • And the increase in the prevalence and diagnosis of type 2 diabetes which will lead to growth of the painful diabetic neuropathy (PDN) market - the largest NP segment.
  • Additionally, the approval of novel formulations and first-in-class therapies in pipeline for NP that will drive sales in this market
  • The greatest barrier to growth in this market will be the fact that the key market leading drugs will go off patent during the forecast period leading to a NP market largely dominated by generics, which raises the barrier to entry for novel drug therapies.

Order a Purchase Copy @ http://www.marketoptimizer.org/contacts/purchase?rname=10714 .

Company Profiles include in Report:

  • Pfizer
  • Eli Lilly
  • Grünenthal
  • Endo Health Solutions
  • Janssen Pharmaceuticals
  • Daiichi Sankyo
  • Convergence Pharmaceuticals

Scope

  • Overview of 3 neuropathic pain indications - painful diabetic neuropathy, Postherpetic neuralgia and trigeminal neuralgia, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized neuropathic pain therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2012 and forecast for 10 years to 2022.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the neuropathic pain therapeutics market.
  • Pipeline analysis: focus on mid to late-stage pipeline drugs discussing emerging trends as well as overview of earlier phase drugs.
  • Analysis of the current and future market competition in the global neuropathic pain therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Inquire for Discount @ http://www.marketoptimizer.org/contacts/discount?rname=10714 .
(This is a premium report priced at US$10995 for a single user License.)

Reasons to buy

  • Develop and design in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
  • Develop business strategies by understanding the trends shaping and driving the global neuropathic pain therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global neuropathic pain therapeutics market in future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Track drug sales in the global neuropathic pain therapeutics market from 2012-2022.

Explore more reports on Pharmaceuticals industry at http://www.marketoptimizer.org/category/life-sciences/pharmaceuticals .

About Us:
MarketOptimizer.org is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Read the full story at http://www.prweb.com/releases/global-neuropathic-pain/market-outlook-to-2022/prweb12203144.htm.


'/>"/>
Source: PRWeb
Copyright©2014 Vocus, Inc.
All rights reserved

Related medicine news :

1. Cebranopadol Neuropathic Pain Treatment Market Analysis & Forecasts to 2022 Report Available at ReportsnReports.com
2. Pain Management Therapeutics Market to 2019 - Impact of Patent Expiries Offset by Demand for Neuropathic and Rheumatoid Pain Medications and Strong Pipeline
3. NYSE Closing Bell Rings to Honor Millions with Neuropathy and Neuropathic Pain
4. For some, deep brain stimulation brings lasting improvement in neuropathic pain
5. Global Market for Tissue Engineering and Regeneration to Reach $56.9 Billion in 2019; Favorable Government Policies Driving North American and European Markets
6. Global Neurostimulation Devices Market Is Expected To Be Worth $8,791.8 Million By 2020: Grand View Research, Inc
7. New Post from Bedros Keuilian Explains Difference Between Spending on Fitness Marketing and Investing In It
8. Global Medical Robotic Systems Market Will Be Driven By Infusion Of Technology In Medical Devices Industry From 2014 To 2020: Grand View Research, Inc.
9. Market Publishers Ltd Announced as Media Partner of The Evolution Summit 2014
10. PartsSource Launches Healthcare's First Online Service Parts Marketplace
11. 12.8% CAGR for Omega-3 PUFA Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/13/2019)... ... June 13, 2019 , ... Hard money lenders like Monroe ... and the funds can also be provided quickly. If the documentation and collateral are ... are able to avoid the federal oversight involved with a traditional lender, which allows ...
(Date:6/13/2019)... ... 2019 , ... Many people with back pain that radiates down their legs ... widely misunderstood and so are its treatments, according to Kaliq Chang, MD, double board-certified ... , “Sciatica is commonly used to describe nerve-like pain traveling down the legs, often ...
(Date:6/13/2019)... ... June 13, 2019 , ... GlycoMark, Inc. ... at the American Diabetes Association (ADA) Scientific Sessions 2019 involving the GlycoMark test ... an SGLT-2 inhibitor. SGLT-2 inhibitors are used to lower glucose levels in patients ...
(Date:6/12/2019)... ... June 12, 2019 , ... In September of 2018, NVNA and Hospice ... and remote patient monitoring. Following its full-scale launch in March, NVNA has expanded its ... the beginning of 2019, NVNA has achieved an average all-cause hospital readmissions rate of ...
(Date:6/11/2019)... ... June 11, 2019 , ... ... and developmental disabilities and their families recently received the promise of a two-million-dollar ... grant, gifted by The Tomlinson Foundation, would allow TERI to complete phase two ...
Breaking Medicine News(10 mins):
(Date:6/12/2019)... ... June 12, 2019 , ... Through their Sidewalk Angels Foundation (SWA), Marisol ... importance of protecting your entire family from Lyme and other tick-borne diseases. We are ... fur we have. , Through this partnership SWA and GLA look to raise ...
(Date:6/11/2019)... ... , ... Today NASH kNOWledge hosted a Liver Disease Information ... Steatohepatitis (NASH) Day, a global effort in the fight against NASH. Community leaders ... what they can do to help. The event also included a pre-screening of ...
(Date:6/11/2019)... China, and SAN DIEGO (PRWEB) , ... June ... ... and fully integrated global Contract Development and Manufacturing Organization (CDMO) serving the global ... announced the appointment of Wei Chen, Ph.D as the company's new Chief Executive ...
Breaking Medicine Technology: